A289 SAPIEN ® transcatheter implantation therapy versus drug treatment with or without aortic balloon valvoplasty. The outcomes used were effectiveness (as measured by clinical outcomes chance of successful implantation procedure and survival) and safety. The results were expressed as the reason of incremental cost-effectiveness ratio (ICER) per years saved and years free from serious adverse events. Probabilistic sensitivity analysis was performed on the main parameters of the model. RESULTS: Compared with medical therapy with or without aortic balloon valvuloplasty, the employment of the SAPIEN ® valve presents safety in the procedure, increased survival and compatible ICER -US$ 40.000/life of year saved. CONCLUSIONS: The use of SAPIEN ® transcatheter implantation results in improved survival and functional improvement in patients with low risk of serious adverse events, and demonstrates a costeffectiveness profile when compared to other technologies already incorporated by the Brazilian public health system.
OBJECTIVES:
To evaluate the cost-effectiveness of apixaban compared to enoxaparin, rivaroxaban and dabigatran in venous thromboembolism prevention (VTEp) in patients undergoing elective total knee or hip replacement (TKR, THR) from the private payer's perspective in Colombia. METHODS: An economic model, including both a decision tree component and a Markov model was created to compare apixaban 5mg/day, enoxaparin 40mg/day, dabigatran 220mg/day and rivaroxaban 10mg/day. The decision tree considers potential VTE, bleeding, death events as well as no-events which occur over the shortterm and lends itself to model the prophylactic and post-prophylactic phases over the first 90 days post-surgery. Events that occur over the long term are modeled using a Markov structure, which provides the option to simulate events such as recurrent VTE and post-thrombotic syndrome. The model relies upon the results from a mixed treatment comparison study for key efficacy and safety inputs, information from published literature for unit cost and utility data, and Colombian cost and patterns of care study for resource use and event costs. Results are reported as cost per quality-adjusted life years gained (QALY's) and life years gained (LYG) over a prophylaxis + five-year time horizon. A discount rate of 3.5% was used for both costs and outcomes. RESULTS: Results indicate that the use of apixaban is dominant compared to enoxaparin and dabigatran in the overall population for THR and TKR (less number of VTE events, total bleeds and deaths which generated higher number QALYs and lower overall costs). When compared to rivaroxaban the model results show similar long-term gains in QALY's and LYG for apixaban, as well as similar costs -showing small savings for apixaban mainly due to lower bleeding costs. CONCLUSIONS: Apixaban is a cost-effective alternative in preventing VTE in patients undergoing THR or TKR in Colombian private setting.
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COST-EFFECTIVENESS OF THROMBOLYSIS FOR MYOCARDIAL INFARCTION WITH SUPRA ST IN COLOMBIA
Rosselli D 1 , Rueda JD 1 , Moreno A 1 , Herran S 2 1 Pontificia Universidad Javeriana, Bogota, Colombia, 2 Boehringer Ingelheim, Bogota, Bogota, Colombia OBJECTIVES: Most patients with myocardial infarction in Colombia are treated with streptokynase, despite tenecteplase being recognized as more effective. Our objective was to evaluate the cost-effectiveness and cost-utility of tenecteplase, compared with streptokinase, in the treatment of ST elevation myocardial infarction. METHODS: We designed a decision tree model, from the perspective of the Colombian health system. We calculated quality adjusted life years (QALY) gained (using data Tuft's registry), as well as cost per death, and cost per major outcome averted (death, stroke, severe heart failure). The costs were estimated in Colombian pesos for 2012 (Exchange rate 1US$=COP$1785) using national tariff manuals (Social Security 2001 with inflation adjustment) and resource use obtained from our local university hospital, validated by national expert panel. We performed a probabilistic and deterministic sensitivity analysis. RESULTS: The average total cost for a tenecteplase treated patient was US$1456. The cost per incremental QALY gained with tenecteplase was US$14,447; US$95,302 per death averted, and US$38,578 for major outcome averted. The average total cost for the treatment of acute phase of all myocardial infarctions for 2012 was estimated in US$728,000. Monte Carlo simulation acceptability curve showed that in 85% of the trials the result would be cost-effective, assuming a willingness to pay of up to three times the per capita gross domestic product (Colombia's per capita GDP is US$6723). If the cost of tenecteplase were lowered from US$2066 to US$389 the cost per QALY would reach the one per capita GDP threshold. CONCLUSIONS: Our results suggest that tenecteplase is cost effective if we accept the three-times per capita GDP threshold. 
PCV98 ECONOMIC EVALUATION OF TICAGRELOR IN TREATING PATIENTS WITH ACUTE CORONARY SYNDROME IN HONG KONG: A COST-UTILITY ANALYSIS
OBJECTIVES:
The multi-centered, double-blind, randomized PLATO trial on 18,624 patients from 43 countries has demonstrated that ticagrelor was superior in reducing the rates of cardiovascular mortality, myocardial infarction (MI), or stroke among patients with acute coronary syndrome (ACS) compared to clopidogrel but without a significant increase in major bleedings. This study aimed to evaluate the long-term cost-effectiveness of ticagrelor plus acetylsalicylic acid (ASA) versus clopidogrel plus ASA in ACS patients in Hong Kong (HK) from a public hospital's perspective. METHODS: A two-phase state-transition Markov model was developed to estimate the long-term economic and health outcomes measured as qualityadjusted life years (QALYs). PLATO data were utilized to estimate patients' resource use (incl. hospitalization bed days, investigations, interventions and blood products), rate of cardiovascular events (i.e. MI and stroke) and QALYs for the first year. Outcomes from the second year onwards were extrapolated using results from the first year. Direct health care costs were HK-specific and utility data were adopted from published literature. Time horizons were set at 1 year, 5 years and patients' lifetime. All costs which were presented as 2012 figures and effectiveness were both discounted at 3% per annum. A series of one-way and multi-way sensitivity analyses were performed to test model robustness. RESULTS: Over a lifetime horizon, the use of ticagrelor led to improved clinical outcome with a discounted survival of 13.08 QALYs per patient in the ticagrelor treatment group compared to 12.91 in the clopidogrel treatment group. Despite its higher daily cost, ticagrelor was predicted to significantly reduce resource utilization by HKD6,348 (USD814, 1USD=7.8HKD) and stroke treatment cost by HKD45,226 (USD5,798) per patient which can be translated into a heavy public health care expenditure. CONCLUSIONS: The treatment of ACS patients with lifetime use of ticagrelor is considered cost-saving compared with clopidogrel from a public health care provider perspective in HK. OBJECTIVES: Atrial fibrillation (AF) is a chronic, progressive disease characterized by uncoordinated atrial activation involving a rapid and irregular heartbeat. Its prevalence has been increasing worldwide. Antiarrhythmic drug therapy is a commonly-used treatment for paroxysmal AF, and catheter ablation has become an important treatment alternative. The purpose of this study was to assess the cost-effectiveness of catheter ablation compared to antiarrhythmic drug (AAD) therapy for the treatment of paroxysmal AF in Canada. METHODS: A simulation model was developed for a hypothetical cohort of 55-year-old patients with drug-refractory paroxysmal AF and a low stroke risk. The first year was modeled with a decision tree. Years 2 and beyond were modeled with a Markov simulation. The model treatment arms were catheter ablation and AAD mono-therapy. The model was created to assess costs and quality-adjusted lifeyears over a lifetime horizon. Clinical efficacy of catheter ablation and AAD therapy were modeled based on the results of a recently-published randomized controlled trial (Wilber et al., 2010) . Utilities and state transition probabilities were drawn from the published literature. Costs were specific to Canada. RESULTS: The incremental cost-effectiveness ratio for catheter ablation versus AAD therapy ranged from CAD$10,000 to a dominant strategy (cost less and is more effective) per quality-adjusted life-year. Over a lifetime horizon, the quality-adjusted life expectancy ranged from 11.25 to 11.75 years for catheter ablation compared to 10.75 to 11.25 years for AAD therapy. The results were robust in sensitivity analysis. Results were most sensitive to ablation costs, probability of successful ablation treatment, and probability of revision to AF. CONCLUSIONS: Catheter ablation appears to be cost-effective compared to AAD therapy among patients who had drug refractory paroxysmal AF in the Canadian population when using a cost-effectiveness threshold of CAD$50,000. Further research is necessary to understand the effect of newly approved OAC therapies.
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COST-EFFECTIVENESS OF CATHETER ABLATION VERSUS ANTIARRHYTHMIC DRUG THERAPY FOR THE TREATMENT OF ATRIAL FIBRILLATION IN CANADA
PCV100 TOWARDS A PARADIGM SHIFT IN ANTICOAGULATION? TOO SOON TO CONCLUDE ON COST-EFFECTIVENESS OF NEW ANTICOAGULANTS
Hagen G, Wisloff T NOKC, Oslo, Norway OBJECTIVES: To evaluate the cost-effectiveness of new oral anticoagulants (apixaban, dabigatran and rivaroxaban) compared relative to each other and relative to warfarin for stroke prevention in patients with atrial fibrillation.
METHODS:
We developed a decision analytic model, designed as a probabilistic Markov model containing 200 different probability distributions. The model included eight health states; atrial fibrillation (AF), heart failure, moderate stroke sequela, severe stroke sequela, atrial fibrillation with previous AMI, atrial fibrillation with previous stroke, atrial fibrillation with major gastrointestinal bleeding and dead. Efficacy data was collected from a recently published report from the Canadian Health Technology Assessment Agency (CADTH). Epidemiological input data was gathered from registries. Data on Quality of Life were based on published EQ-5D data and costs were mainly based on national tariffs. The analysis was stratified according to risk of stroke as measured by CHA2DS2-VASc and risk of bleeding as measured by HAS-BLED. RESULTS: When the new drugs were compared relative to each other for medium risk patients, simulations indicated a 41% probability that apixaban is cost-effective, with 34% and 24% for dabigatran and rivaroxaban, respectively. For high risk patients, simulations indicated a 56% probability that dabigatran is cost-effective, with 29% and 15% for apixaban and rivaroxaban, respectively. When comparing each of the new anticoagulants with the old (warfarin), analyses indicate a probability between 21% and 60% that warfarin is still cost-effective. In separate analyses,
